E-Book Description
Hematology 2020 AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM PDF Free Download
Welcome to the 62nd annual meeting of the American Society of Hematology. This year’s congress is unique among ASH annual meetings—the first to be all-virtual and the first to be held in the midst of a raging pandemic.
And just as the annual meeting has had to adapt to the circumstances, so too has Hematology 2020. For the first time, this year’s edition is electronic-only. Some of the chapters reference COVID-19 and its impact on hematologic disorders. Other new features include a new page design, visual abstracts, and shorter manuscripts with the aim of making Hematology more graphical.
In spite of these changes, the essence of Hematology remains the same. As always, you can count on high quality content spanning the breadth of malignant and nonmalignant hematology, based on a state-of-the-art Education Program prepared by this year’s Ed- ucation Co-Chairs, Dr. Sioban Keel and Dr. Christopher Flowers. Dr. Andrew Roberts will deliver the Ham-Wasserman Lecture on Therapeutic Development and Current Uses of BCL-2 Inhibition, and his article is also included.
This volume is the culmination of the efforts of many individuals and their selfless com- mitment to ASH, including the authors, reviewers, designer (Debra Naylor), and ASH staff (Michelle Lee, Kenneth April, and Brian Cannon).
In these difficult times, we hope that you find Hematology to be the valued resource that it has always strived to be: a means of helping you keep current with the torrid pace of progress in hematology by highlighting recent practice-changing clinical advances as well as putting cutting edge basic advances into clinical context. Happy reading, and please stay safe.
E-Book Details
Table of Contents
x Editors’ Message xi Reviewers
xii Continuing Medical Education Information
Ham-Wasserman Lecture
1 Therapeutic development and current uses of BCL-2 inhibition
ANDREW W. ROBERTS
A Map for the Changing Landscape of CLL
10 Approaches for relapsed CLL after chemotherapy-free frontline regimens
LINDSEY E. ROEKER AND ANTHONY R. MATO
18 EVIDENCE-BASED MINIREVIEW
Treatment of relapsed chronic lymphocytic leukemia after venetoclax MEGHAN C. THOMPSON AND ANTHONY R. MATO
24 Chemotherapy-free frontline therapy for CLL: is it worth it?
JOANNA M. RHODES AND JACQUELINE C. BARRIENTOS
33 Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy
CAROL MORENO
Acute Myeloid Leukemia—So Many Treatment Options; How Do You Decide?
41 Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?
EVAN C. CHEN AND JACQUELINE S. GARCIA
51 How to approach shared decision making when determining consolidation, maintenance therapy, and transplantation in acute myeloid leukemia
ALISON R. WALKER
57 Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop
EUNICE S. WANG AND JEFFREY BARON
Advances in the Laboratory Assessment of Hemostatic and Thrombotic Disorders
67 “TEG talk”: expanding clinical roles for thromboelastography and rotational thromboelastometry RITA SELBY
76 Improving interpretation of genetic testing for hereditary hemorrhagic, thrombotic, and platelet disorders
MICHELE P. LAMBERT
82 EVIDENCE-BASED MINIREVIEW
Laboratory surveillance of immune-mediated thrombotic thrombocytopenic purpura ANG LI AND JOHANNA A. KREMER HOVINGA
Hematology 2020 |
ASH Education Program
Aggressive Lymphomas: What Novel Approaches Are Ready for Prime Time?
85 Can we use epigenetics to prime chemoresistant lymphomas?
JENNIFER E. AMENGUAL
95 Harnessing lymphoma epigenetics to improve therapies*
HAOPENG YANG AND MICHAEL R. GREEN
101 Novel targets in aggressive lymphoma
KAMI MADDOCKS
Beyond the Marrow
107 Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes
CARMEM BONFIM
115 Extrahematopoietic manifestations of the short telomere syndromes
KRISTEN E. SCHRATZ
Caring for Patients with Acute Leukemia in Community Hospitals: Who, What, and When to Refer?
123 Optimizing management of acute leukemia in community centers and when to refer
ANAND P. JILLELLA, JORGE E. CORTES, AND VAMSI K. KOTA
129 Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings
ANNA B. HALPERN AND ROLAND B. WALTER
135 Updates in infection risk and management in acute leukemia
C. LOGAN, D. KOURA, AND R. TAPLITZ
Challenging Situations for Patients with Aggressive Lymphomas
140 Approaches to aggressive B-cell lymphomas in less fit patients
NANCY L. BARTLETT
148 Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas
OREOFE O. ODEJIDE
154 Strategies for aggressive T-cell lymphoma: divide and conquer
LAUREN C. PINTER-BROWN
Chronic Transfusion Support: Challenging Cases
160 Challenges in chronic transfusion for patients with thalassemia
ASHUTOSH LAL
167 Outpatient transfusions for myelodysplastic syndromes
ERICA M. WOOD AND ZOE K. MCQUILTEN
175 Social aspects of chronic transfusions: addressing social determinants of health, health literacy, and quality of life
JENNIFER WEBB
Diagnostic and Prognostic Models in VTE Management: Ready for Prime Time?
184 Can pregnancy-adapted algorithms avoid diagnostic imaging for pulmonary embolism?
WEE-SHIAN CHAN
190 When I treat a patient with acute pulmonary embolism at home
FREDERIKUS A. KLOK AND MENNO V. HUISMAN
195 EVIDENCE-BASED MINIREVIEW
Advanced therapies and extracorporeal membrane oxygenation for the management of high-risk pulmonary embolism
RADHIKA GANGARAJU AND FREDERIKUS A. KLOK
201 Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?
FIONNUALA N ́I A ́INLE AND BARRY KEVANE
Genetic Testing for Heritable Hematologic Disorders 101
213 Informed consent for genetic testing in hematology
JONATHAN M. MARRON
219 Identifying potential germline variants from sequencing hematopoietic malignancies
IRA L. KRAFT AND LUCY A. GODLEY
Handling Challenging Questions in the Management of CML
228 First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?
VIVIAN G. OEHLER
237 How to manage CML patients with comorbidities
JORGE CORTES
243 Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?
DELPHINE REA
Immunotherapy in Multiple Myeloma
248 Sequencing multiple myeloma therapies with and after antibody therapies
NIELS W. C. J. VAN DE DONK
259 EVIDENCE-BASED MINIREVIEW
Should all newly diagnosed MM patients receive CD38 antibody–based treatment? CHARLOTTE L. B. M. KORST AND NIELS W. C. J. VAN DE DONK
264 Bispecifics, trispecifics, and other novel immune treatments in myeloma
GUIDO LANCMAN, JOSHUA RICHTER, AND AJAI CHARI
272 Future of CAR T cells in multiple myeloma
KITSADA WUDHIKARN, SHAM MAILANKODY, AND ERIC L. SMITH
Improving Symptom Control for Children with Hematological Malignancies
280 Improving symptom control and reducing toxicities for pediatric patients with hematological malignancies
LILLIAN SUNG, TAMARA P. MILLER, AND ROBERT PHILLIPS
Indolent Lymphomas: Answers to Smoldering Questions
287 How do I sequence therapy for follicular lymphoma?
GILLES SALLES
295 How do we sequence therapy for marginal zone lymphomas?
ALESSANDRO BROCCOLI AND PIER LUIGI ZINZANI
306 Transformed lymphoma: what should I do now?
SONALI SMITH
Infection Risk, Immunization Recommendations, and Antimicrobial Prophylaxis
312 Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs
ELISSA R. ENGEL AND JOLAN E. WALTER
Hematology 2020 | ASH Education Program
319 Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases
LUIS MALPICA AND STEPHAN MOLL
328 Preventing infections in children and adults with asplenia
GRACE M. LEE
Managing Toxicities of Targeted Therapies in CLL
336 Managing toxicities of Bruton tyrosine kinase inhibitors
ANDREW LIPSKY AND NICOLE LAMANNA
346 Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors
ASHLEY HANLON AND DANIELLE M. BRANDER
357 Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia
KIRSTEN FISCHER, OTHMAN AL-SAWAF, AND MICHAEL HALLEK
Monoclonal Gammopathies of Determined Significance
363 Management of AL amyloidosis in 2020
GIOVANNI PALLADINI, PAOLO MILANI, AND GIAMPAOLO MERLINI
372 Management of Waldenstro ̈m macroglobulinemia in 2020
JORGE J. CASTILLO AND STEVEN P. TREON
380 Monoclonal gammopathies of clinical significance
ANGELA DISPENZIERI
More Anxiety-Provoking Hematology Consults
389 A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact
ARI ZIMRAN, ROSA RUCHLEMER, AND SHOSHANA REVEL-VILK
395 Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease
KENNETH MCCLAIN
400 Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP
MICHAEL LINENBERGER AND KLEBER Y. FERTRIN
Myelodysplastic Syndromes: What We Have and What We Want
411 Existing agents, novel agents, or transplantation for high-risk MDS
BART L. SCOTT
418 Patient stratification in myelodysplastic syndromes: how a puzzle may become a map
ANNE SOPHIE KUBASCH AND UWE PLATZBECKER
426 Therapy for lower-risk MDS
HETTY E. CARRAWAY AND CANER SAYGIN
Myeloproliferative Disorders: Too Many Cells, Too Few Therapies
434 Applied genomics in MPN presentation
ALISON R. MOLITERNO AND HANNAH KAIZER
440 Genomics of MPN progression
ANAND A. PATEL AND OLATOYOSI ODENIKE
450 Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes
MRINAL M. PATNAIK AND TERRA L. LASHO
460 EVIDENCE-BASED MINIREVIEW
Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review MRINAL M. PATNAIK AND TERRA LASHO
Out of Balance: Anemias Due to Disordered Iron Homeostasis
465 Inherited microcytic anemias
MARIA DOMENICA CAPPELLINI, ROBERTA RUSSO, IMMACOLATA ANDOLFO, AND ACHILLE IOLASCON
471 Global look at nutritional and functional iron deficiency in infancy
MICHAEL B. ZIMMERMANN
478 Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick?
KLEBER YOTSUMOTO FERTRIN
Pediatric Hematological Malignancies: CARs for Kids
487 Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma
EMILY M. HSIEH AND RAYNE H. ROUCE
494 CAR T cells for other pediatric non–B-cell hematologic malignancies ADAM J. LAMBLE AND REBECCA GARDNER
501 CAR T cells vs allogeneic HSCT for poor-risk ALL
CAROLINE DIORIO AND SHANNON L. MAUDE
508 EVIDENCE-BASED MINIREVIEW
What is the role for HSCT or immunotherapy in pediatric hypodiploid B-cell acute lymphoblastic leukemia?
AIMEE C. TALLEUR AND SHANNON L. MAUDE
Platelet Transfusions for Hematology/Oncology Patients
512 Does ABO and RhD matching matter for platelet transfusion?
NANCY M. DUNBAR
518 How well do platelets prevent bleeding?
DARRELL J. TRIULZI
523 EVIDENCE-BASED MINIREVIEW
The use of premedications for platelet transfusions in pediatric patients MEGHAN MCCORMICK AND DARRELL TRIULZI
527 Platelet transfusion refractoriness: How do I diagnose and manage?
CLAUDIA S. COHN
Selected Hemostasis and Thrombosis Topics in Women
533 Management of heavy menstrual bleeding on anticoagulation
BETHANY SAMUELSON BANNOW
538 EVIDENCE-BASED MINIREVIEW
Abnormal uterine bleeding in users of rivaroxabanand apixaban AMANDA E. JACOBSON-KELLY AND BETHANY T. SAMUELSON BANNOW
542 Prevention and treatment of postpartum hemorrhage: focus on hematological aspects of management
CLAIRE MCLINTOCK
Hematology 2020 |
ASH Education Program
547 Women and bleeding disorders: diagnostic challenges
PAULA D. JAMES
The Brain and Pain in Sickle Cell Disease
553 Neuropathic pain in sickle cell disease: measurement and management
ALEXANDER GLAROS AND AMANDA M. BRANDOW
562 Optimizing the management of chronic pain in sickle cell disease
IFEYINWA OSUNKWO, HAZEL F. O’CONNOR, AND ELNA SAAH
The Emerging Role of Targeted Therapies and Cell Therapy in Transplant
570 Next-generation cell therapies: the emerging role of CAR-NK cells
RAFET BASAR, MAY DAHER, AND KATAYOUN REZVANI
579 Practical aspects of building a new immunotherapy program: the future of cell therapy
JESU ́S G. BERDEJA
Understanding How to Manipulate the Immune System in Immunotherapy for Lymphoma
585 Fundamentals of immunology for understanding immunotherapy for lymphoma
STEPHEN M. ANSELL
590 Immunotherapy with cells*
ELISE A. CHONG AND DAVID L. PORTER
598 Immunotherapy with drugs
YUN CHOI AND CATHERINE S. DIEFENBACH
Nonanticoagulant Interventions in Venous Thromboembolism
606 Role of venous stenting for venous thromboembolism
KAREN BREEN
612 Thrombolytic therapy in acute venous thromboembolism
THITA CHIASAKUL AND KENNETH A. BAUER
619 Inferior vena cava filters: a framework for evidence-based use
AMAR H. KELKAR AND ANITA RAJASEKHAR
629 EVIDENCE-BASED MINIREVIEW
Do prophylactic inferior vena cava filters in trauma patients reduce the risk of mortality or pulmonary embolism?
AMAR H. KELKAR AND ANITA RAJASEKHAR
What Hematologists Need to Know About Giving and Stopping Aspirin
634 Does aspirin prevent venous thromboembolism?
ROBERT DIEP AND DAVID GARCIA
642 Combining antiplatelet and anticoagulant therapy in cardiovascular disease
GEOFFREY D. BARNES
Yin and Yang of Autoimmunity and Immunodeficiencies in Hematology
649 Allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency
EMMA C. MORRIS
661 How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation ROSHINI S. ABRAHAM
673 Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs)
MARKUS G. SEIDEL
Erratum
680 Sanz GF. In MDS, is higher risk higher reward? Hematology Am Soc Hematol Educ Program. 2019;2019: 381-390.
*Articles Not Eligible for Continuing Medical Education Credit
95 Harnessing lymphoma epigenetics to improve therapies
HAOPENG YANG AND MICHAEL R. GREEN
590 Immunotherapy with cells
ELISE A. CHONG AND DAVID L. PORTER
Hematology 2020 AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM PDF Ebook
xii Continuing Medical Education Information
Ham-Wasserman Lecture
1 Therapeutic development and current uses of BCL-2 inhibition
ANDREW W. ROBERTS
A Map for the Changing Landscape of CLL
10 Approaches for relapsed CLL after chemotherapy-free frontline regimens
LINDSEY E. ROEKER AND ANTHONY R. MATO
18 EVIDENCE-BASED MINIREVIEW
Treatment of relapsed chronic lymphocytic leukemia after venetoclax MEGHAN C. THOMPSON AND ANTHONY R. MATO
24 Chemotherapy-free frontline therapy for CLL: is it worth it?
JOANNA M. RHODES AND JACQUELINE C. BARRIENTOS
33 Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy
CAROL MORENO
Acute Myeloid Leukemia—So Many Treatment Options; How Do You Decide?
41 Does patient fitness play a role in determining first-line treatment of acute myeloid leukemia?
EVAN C. CHEN AND JACQUELINE S. GARCIA
51 How to approach shared decision making when determining consolidation, maintenance therapy, and transplantation in acute myeloid leukemia
ALISON R. WALKER
57 Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop
EUNICE S. WANG AND JEFFREY BARON
Advances in the Laboratory Assessment of Hemostatic and Thrombotic Disorders
67 “TEG talk”: expanding clinical roles for thromboelastography and rotational thromboelastometry RITA SELBY
76 Improving interpretation of genetic testing for hereditary hemorrhagic, thrombotic, and platelet disorders
MICHELE P. LAMBERT
82 EVIDENCE-BASED MINIREVIEW
Laboratory surveillance of immune-mediated thrombotic thrombocytopenic purpura ANG LI AND JOHANNA A. KREMER HOVINGA
Hematology 2020 |
ASH Education Program
Aggressive Lymphomas: What Novel Approaches Are Ready for Prime Time?
85 Can we use epigenetics to prime chemoresistant lymphomas?
JENNIFER E. AMENGUAL
95 Harnessing lymphoma epigenetics to improve therapies*
HAOPENG YANG AND MICHAEL R. GREEN
101 Novel targets in aggressive lymphoma
KAMI MADDOCKS
Beyond the Marrow
107 Special pre- and posttransplant considerations in inherited bone marrow failure and hematopoietic malignancy predisposition syndromes
CARMEM BONFIM
115 Extrahematopoietic manifestations of the short telomere syndromes
KRISTEN E. SCHRATZ
Caring for Patients with Acute Leukemia in Community Hospitals: Who, What, and When to Refer?
123 Optimizing management of acute leukemia in community centers and when to refer
ANAND P. JILLELLA, JORGE E. CORTES, AND VAMSI K. KOTA
129 Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings
ANNA B. HALPERN AND ROLAND B. WALTER
135 Updates in infection risk and management in acute leukemia
C. LOGAN, D. KOURA, AND R. TAPLITZ
Challenging Situations for Patients with Aggressive Lymphomas
140 Approaches to aggressive B-cell lymphomas in less fit patients
NANCY L. BARTLETT
148 Strategies for introducing palliative care in the management of relapsed or refractory aggressive lymphomas
OREOFE O. ODEJIDE
154 Strategies for aggressive T-cell lymphoma: divide and conquer
LAUREN C. PINTER-BROWN
Chronic Transfusion Support: Challenging Cases
160 Challenges in chronic transfusion for patients with thalassemia
ASHUTOSH LAL
167 Outpatient transfusions for myelodysplastic syndromes
ERICA M. WOOD AND ZOE K. MCQUILTEN
175 Social aspects of chronic transfusions: addressing social determinants of health, health literacy, and quality of life
JENNIFER WEBB
Diagnostic and Prognostic Models in VTE Management: Ready for Prime Time?
184 Can pregnancy-adapted algorithms avoid diagnostic imaging for pulmonary embolism?
WEE-SHIAN CHAN
190 When I treat a patient with acute pulmonary embolism at home
FREDERIKUS A. KLOK AND MENNO V. HUISMAN
195 EVIDENCE-BASED MINIREVIEW
Advanced therapies and extracorporeal membrane oxygenation for the management of high-risk pulmonary embolism
RADHIKA GANGARAJU AND FREDERIKUS A. KLOK
201 Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?
FIONNUALA N ́I A ́INLE AND BARRY KEVANE
Genetic Testing for Heritable Hematologic Disorders 101
213 Informed consent for genetic testing in hematology
JONATHAN M. MARRON
219 Identifying potential germline variants from sequencing hematopoietic malignancies
IRA L. KRAFT AND LUCY A. GODLEY
Handling Challenging Questions in the Management of CML
228 First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic phase chronic myeloid leukemia?
VIVIAN G. OEHLER
237 How to manage CML patients with comorbidities
JORGE CORTES
243 Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?
DELPHINE REA
Immunotherapy in Multiple Myeloma
248 Sequencing multiple myeloma therapies with and after antibody therapies
NIELS W. C. J. VAN DE DONK
259 EVIDENCE-BASED MINIREVIEW
Should all newly diagnosed MM patients receive CD38 antibody–based treatment? CHARLOTTE L. B. M. KORST AND NIELS W. C. J. VAN DE DONK
264 Bispecifics, trispecifics, and other novel immune treatments in myeloma
GUIDO LANCMAN, JOSHUA RICHTER, AND AJAI CHARI
272 Future of CAR T cells in multiple myeloma
KITSADA WUDHIKARN, SHAM MAILANKODY, AND ERIC L. SMITH
Improving Symptom Control for Children with Hematological Malignancies
280 Improving symptom control and reducing toxicities for pediatric patients with hematological malignancies
LILLIAN SUNG, TAMARA P. MILLER, AND ROBERT PHILLIPS
Indolent Lymphomas: Answers to Smoldering Questions
287 How do I sequence therapy for follicular lymphoma?
GILLES SALLES
295 How do we sequence therapy for marginal zone lymphomas?
ALESSANDRO BROCCOLI AND PIER LUIGI ZINZANI
306 Transformed lymphoma: what should I do now?
SONALI SMITH
Infection Risk, Immunization Recommendations, and Antimicrobial Prophylaxis
312 Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs
ELISSA R. ENGEL AND JOLAN E. WALTER
Hematology 2020 | ASH Education Program
319 Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases
LUIS MALPICA AND STEPHAN MOLL
328 Preventing infections in children and adults with asplenia
GRACE M. LEE
Managing Toxicities of Targeted Therapies in CLL
336 Managing toxicities of Bruton tyrosine kinase inhibitors
ANDREW LIPSKY AND NICOLE LAMANNA
346 Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors
ASHLEY HANLON AND DANIELLE M. BRANDER
357 Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia
KIRSTEN FISCHER, OTHMAN AL-SAWAF, AND MICHAEL HALLEK
Monoclonal Gammopathies of Determined Significance
363 Management of AL amyloidosis in 2020
GIOVANNI PALLADINI, PAOLO MILANI, AND GIAMPAOLO MERLINI
372 Management of Waldenstro ̈m macroglobulinemia in 2020
JORGE J. CASTILLO AND STEVEN P. TREON
380 Monoclonal gammopathies of clinical significance
ANGELA DISPENZIERI
More Anxiety-Provoking Hematology Consults
389 A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact
ARI ZIMRAN, ROSA RUCHLEMER, AND SHOSHANA REVEL-VILK
395 Histiocytic disorders: insights into novel biology and implications for therapy of Langerhans cell histiocytosis and Erdheim-Chester disease
KENNETH MCCLAIN
400 Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP
MICHAEL LINENBERGER AND KLEBER Y. FERTRIN
Myelodysplastic Syndromes: What We Have and What We Want
411 Existing agents, novel agents, or transplantation for high-risk MDS
BART L. SCOTT
418 Patient stratification in myelodysplastic syndromes: how a puzzle may become a map
ANNE SOPHIE KUBASCH AND UWE PLATZBECKER
426 Therapy for lower-risk MDS
HETTY E. CARRAWAY AND CANER SAYGIN
Myeloproliferative Disorders: Too Many Cells, Too Few Therapies
434 Applied genomics in MPN presentation
ALISON R. MOLITERNO AND HANNAH KAIZER
440 Genomics of MPN progression
ANAND A. PATEL AND OLATOYOSI ODENIKE
450 Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes
MRINAL M. PATNAIK AND TERRA L. LASHO
460 EVIDENCE-BASED MINIREVIEW
Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review MRINAL M. PATNAIK AND TERRA LASHO
Out of Balance: Anemias Due to Disordered Iron Homeostasis
465 Inherited microcytic anemias
MARIA DOMENICA CAPPELLINI, ROBERTA RUSSO, IMMACOLATA ANDOLFO, AND ACHILLE IOLASCON
471 Global look at nutritional and functional iron deficiency in infancy
MICHAEL B. ZIMMERMANN
478 Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): is too little iron making your patient sick?
KLEBER YOTSUMOTO FERTRIN
Pediatric Hematological Malignancies: CARs for Kids
487 Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma
EMILY M. HSIEH AND RAYNE H. ROUCE
494 CAR T cells for other pediatric non–B-cell hematologic malignancies ADAM J. LAMBLE AND REBECCA GARDNER
501 CAR T cells vs allogeneic HSCT for poor-risk ALL
CAROLINE DIORIO AND SHANNON L. MAUDE
508 EVIDENCE-BASED MINIREVIEW
What is the role for HSCT or immunotherapy in pediatric hypodiploid B-cell acute lymphoblastic leukemia?
AIMEE C. TALLEUR AND SHANNON L. MAUDE
Platelet Transfusions for Hematology/Oncology Patients
512 Does ABO and RhD matching matter for platelet transfusion?
NANCY M. DUNBAR
518 How well do platelets prevent bleeding?
DARRELL J. TRIULZI
523 EVIDENCE-BASED MINIREVIEW
The use of premedications for platelet transfusions in pediatric patients MEGHAN MCCORMICK AND DARRELL TRIULZI
527 Platelet transfusion refractoriness: How do I diagnose and manage?
CLAUDIA S. COHN
Selected Hemostasis and Thrombosis Topics in Women
533 Management of heavy menstrual bleeding on anticoagulation
BETHANY SAMUELSON BANNOW
538 EVIDENCE-BASED MINIREVIEW
Abnormal uterine bleeding in users of rivaroxabanand apixaban AMANDA E. JACOBSON-KELLY AND BETHANY T. SAMUELSON BANNOW
542 Prevention and treatment of postpartum hemorrhage: focus on hematological aspects of management
CLAIRE MCLINTOCK
Hematology 2020 |
ASH Education Program
547 Women and bleeding disorders: diagnostic challenges
PAULA D. JAMES
The Brain and Pain in Sickle Cell Disease
553 Neuropathic pain in sickle cell disease: measurement and management
ALEXANDER GLAROS AND AMANDA M. BRANDOW
562 Optimizing the management of chronic pain in sickle cell disease
IFEYINWA OSUNKWO, HAZEL F. O’CONNOR, AND ELNA SAAH
The Emerging Role of Targeted Therapies and Cell Therapy in Transplant
570 Next-generation cell therapies: the emerging role of CAR-NK cells
RAFET BASAR, MAY DAHER, AND KATAYOUN REZVANI
579 Practical aspects of building a new immunotherapy program: the future of cell therapy
JESU ́S G. BERDEJA
Understanding How to Manipulate the Immune System in Immunotherapy for Lymphoma
585 Fundamentals of immunology for understanding immunotherapy for lymphoma
STEPHEN M. ANSELL
590 Immunotherapy with cells*
ELISE A. CHONG AND DAVID L. PORTER
598 Immunotherapy with drugs
YUN CHOI AND CATHERINE S. DIEFENBACH
Nonanticoagulant Interventions in Venous Thromboembolism
606 Role of venous stenting for venous thromboembolism
KAREN BREEN
612 Thrombolytic therapy in acute venous thromboembolism
THITA CHIASAKUL AND KENNETH A. BAUER
619 Inferior vena cava filters: a framework for evidence-based use
AMAR H. KELKAR AND ANITA RAJASEKHAR
629 EVIDENCE-BASED MINIREVIEW
Do prophylactic inferior vena cava filters in trauma patients reduce the risk of mortality or pulmonary embolism?
AMAR H. KELKAR AND ANITA RAJASEKHAR
What Hematologists Need to Know About Giving and Stopping Aspirin
634 Does aspirin prevent venous thromboembolism?
ROBERT DIEP AND DAVID GARCIA
642 Combining antiplatelet and anticoagulant therapy in cardiovascular disease
GEOFFREY D. BARNES
Yin and Yang of Autoimmunity and Immunodeficiencies in Hematology
649 Allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency
EMMA C. MORRIS
661 How to evaluate for immunodeficiency in patients with autoimmune cytopenias: laboratory evaluation for the diagnosis of inborn errors of immunity associated with immune dysregulation ROSHINI S. ABRAHAM
673 Treatment of immune-mediated cytopenias in patients with primary immunodeficiencies and immune regulatory disorders (PIRDs)
MARKUS G. SEIDEL
Erratum
680 Sanz GF. In MDS, is higher risk higher reward? Hematology Am Soc Hematol Educ Program. 2019;2019: 381-390.
*Articles Not Eligible for Continuing Medical Education Credit
95 Harnessing lymphoma epigenetics to improve therapies
HAOPENG YANG AND MICHAEL R. GREEN
590 Immunotherapy with cells
ELISE A. CHONG AND DAVID L. PORTER
Hematology 2020 AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM PDF Ebook
About the Authors
Adam Cuker, MD, MS
Executive Editor, Hematology 2020 Associate Professor of Medicine Perelman School of Medicine University of Pennsylvania Philadelphia, PA
Mario Cazzola, MD
Deputy Editor, Hematology 2020
Research Group Leader on Myeloid Neoplasms
Fondazione IRCCS Policlinico San Matteo and University of Pavia Pavia, Italy
Stella T. Chou, MD
Deputy Editor, Hematology 2020 Associate Professor of Pediatrics
The Children’s Hospital of Philadelphia University of Pennsylvania Philadelphia, PA
Ann LaCasce, MD, MSc
Deputy Editor, Hematology 2020 Associate Professor of Medicine Dana-Farber Cancer Institute Boston, MA
David Garcia, MD
Special Section Editor, Hematology 2020 Professor of Medicine
University of Washington
Seattle Cancer Care Alliance
Seattle, WA
Executive Editor, Hematology 2020 Associate Professor of Medicine Perelman School of Medicine University of Pennsylvania Philadelphia, PA
Mario Cazzola, MD
Deputy Editor, Hematology 2020
Research Group Leader on Myeloid Neoplasms
Fondazione IRCCS Policlinico San Matteo and University of Pavia Pavia, Italy
Stella T. Chou, MD
Deputy Editor, Hematology 2020 Associate Professor of Pediatrics
The Children’s Hospital of Philadelphia University of Pennsylvania Philadelphia, PA
Ann LaCasce, MD, MSc
Deputy Editor, Hematology 2020 Associate Professor of Medicine Dana-Farber Cancer Institute Boston, MA
David Garcia, MD
Special Section Editor, Hematology 2020 Professor of Medicine
University of Washington
Seattle Cancer Care Alliance
Seattle, WA
Download Links
